Sable Bio
Entity

  • Sable Bio

    Created in 2023
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups

  • Social networks

    645

  • Activities

    deeptech biotech

  • Technologies

    Data Analytics A.I. Synthetic Biology

  • Entity types

    Startup

  • Location

    London, UK

    London

    United Kingdom

  • Employees

    Scale: 2-10

    Estimated: 7

  • Engaged corporates

    0
    0 0

  • Added in Motherbase

    2 months, 2 weeks ago
Description
  • Value proposition

    Empowering Discovery: Precision Insights for Safer Drug Targets.

    Prevent target safety failures with unique data insights and cutting-edge approaches.
    ‍
    Better prediction of drug safety could help patients and prevent hugely costly trial failures. Our advanced workflows assess clinical side effects and predict potential risks for drugs in development using a suite of data modalities.

    Empower your drug development process with our state-of-the-art solutions. Build trust with industry-leading validation across several proof points. Gain deeper insights into target safety, minimize risks, and optimize assay validation strategies.

  • Sable – Reinventing Drug Safety with AI-Powered Data

    We reinvent drug safety through cutting-edge AI-driven data and predictive analytics. Empowering researchers with state-of-the-art tools that integrate and expand on multimodal evidence, we propel the development of safe and effective medicines.

    • https://sablebio.com/
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Last news
Show all articles
Social network dynamics